Drug General Information
Drug ID	D0T6CN
Former ID	DIB008628
Drug Name	BL-8040
Indication	Acute myeloid leukemia [ICD9: 205; ICD10:C92.0]		Phase 2	[525271]
Company	Biolinerx
Structure		Download 2D MOL
Target and Pathway
Target(s)	C-X-C chemokine receptor 4	Target Info	Antagonist	[550382]
KEGG Pathway	Cytokine-cytokine receptor interaction
	Chemokine signaling pathway
	Endocytosis
	Axon guidance
	Leukocyte transendothelial migration
	Intestinal immune network for IgA production
	Pathways in cancer
NetPath Pathway	IL2 Signaling Pathway
	IL4 Signaling Pathway
	Leptin Signaling Pathway
PANTHER Pathway	Axon guidance mediated by Slit/Robo
	Inflammation mediated by chemokine and cytokine signaling pathway
Pathway Interaction Database	S1P3 pathway
	CXCR4-mediated signaling events
	Syndecan-4-mediated signaling events
	HIF-1-alpha transcription factor network
	Ephrin B reverse signaling
Reactome	Binding and entry of HIV virion
	Chemokine receptors bind chemokines
	G alpha (i) signalling events
WikiPathways	GPCRs, Class A Rhodopsin-like
	Hematopoietic Stem Cell Differentiation
	HIV Life Cycle
	Cardiac Progenitor Differentiation
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 525271	ClinicalTrials.gov (NCT02502968) BL-8040 Addition to Consolidation Therapy in AML Patients.
Ref 550382	The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. November 15, 2013; Blood: 122 (21).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.